OBIO®, through its Life Sciences Critical Technology and Commercialization (LSCTC) Centre for Excellence, is advancing the adoption of the Extubation Advisor (EA), an AI-powered clinical decision support tool, at The Ottawa Hospital (TOH) and Unity Health Toronto. Developed by Canadian company Therapeutic Monitoring Systems Inc. (TMS), the EA is designed to help intensive care unit (ICU) clinicians make more informed and timely decisions about when to remove mechanical ventilation from critically ill patients—a process known as extubation. Extubation is a critical moment in ICU care, requiring careful assessment of a patient’s respiratory stability, mental status, and overall condition. Premature extubation can lead to respiratory failure, while delayed extubation increases the risk of complications such as pneumonia, prolonged ICU stays, and higher mortality. The EA uses artificial intelligence to analyze real-time patient data—including vital signs, blood gas levels, and respiratory patterns—to provide clinicians with evidence-based recommendations on the optimal timing for extubation. The tool underwent rigorous evaluation at TOH and Unity Health Toronto, where it demonstrated strong performance in predicting successful extubation outcomes. These trials showed that the EA could improve clinical decision-making, reduce the risk of unplanned reintubation, and support more consistent care across different providers. Based on these positive results, the hospital system has officially adopted the EA as part of its ICU workflow. OBIO®’s support through the LSCTC Centre for Excellence plays a key role in accelerating the integration of innovative health technologies like the EA into clinical practice. The LSCTC focuses on de-risking and scaling life sciences innovations by providing technical, regulatory, and commercialization expertise. By backing the EA’s deployment, OBIO® is helping to bridge the gap between AI innovation and real-world healthcare delivery. The adoption of the Extubation Advisor reflects a broader trend in healthcare toward leveraging AI to enhance clinical decision-making, improve patient outcomes, and optimize resource use. As hospitals face increasing pressure to manage complex cases efficiently, tools like the EA offer data-driven support that complements clinician expertise without replacing it. TMS, the developer of the EA, has positioned itself as a leader in AI-driven clinical monitoring solutions. The company emphasizes the importance of transparency, safety, and regulatory compliance in its AI tools, ensuring they meet the high standards required for medical use. The EA has undergone thorough validation and is designed to operate as a supportive system, not an autonomous decision-maker. The success of the EA at TOH and Unity Health Toronto may serve as a model for other hospitals considering similar AI tools. With rising interest in digital health innovation, the integration of AI into critical care settings is expected to grow, provided that tools are proven effective, safe, and ethically deployed. This initiative also highlights the importance of public-private partnerships in accelerating the adoption of life sciences technologies. By combining the innovation capacity of Canadian startups like TMS with the clinical infrastructure and research capabilities of major hospitals and organizations like OBIO®, Canada is strengthening its position as a hub for health technology advancement. As healthcare systems worldwide seek to improve outcomes and efficiency, AI-powered tools like the Extubation Advisor represent a promising step forward—offering clinicians smarter, faster, and more reliable support in high-stakes clinical decisions.